{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:41:40Z","timestamp":1793032900667,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004024","name":"Jinan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474009"],"award-info":[{"award-number":["82474009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82504925"],"award-info":[{"award-number":["82504925"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ijpx.2026.100586","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:43:30Z","timestamp":1781567010000},"page":"100586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integrating in vitro aerosol characterization and cross-species PBPK modeling to predict human lung exposure of inhaled therapeutic proteins"],"prefix":"10.1016","volume":"12","author":[{"given":"Jin-long","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-xia","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-jia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-xin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2026.100586_bb0005","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.4049\/jimmunol.136.9.3329","article-title":"Interferon-gamma binds to high and low affinity receptor components on murine macrophages","volume":"136","author":"Aiyer","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/faat.1995.1144","article-title":"A multiple-path model of particle deposition in the rat lung","volume":"28","author":"Anjilvel","year":"1995","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3109\/08958378.2014.935535","article-title":"Computational modeling of nanoscale and microscale particle deposition, retention and dosimetry in the mouse respiratory tract","volume":"26","author":"Asgharian","year":"2014","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejpb.2005.04.009","article-title":"Non-invasive pulmonary aerosol delivery in mice by the endotracheal route","volume":"61","author":"Bivas-Benita","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2026.100586_bb0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/jir.1983.3.465","article-title":"Internalization and degradation of human alpha-a interferon bound to bovine MDBK cells: regulation of the decay and resynthesis of receptors","volume":"3","author":"Branca","year":"1983","journal-title":"J. Interf. Res."},{"key":"10.1016\/j.ijpx.2026.100586_bb0030","first-page":"11","article-title":"Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease-antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study","author":"Brantly","year":"2025","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ijpx.2026.100586_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cbi.2015.05.025","article-title":"A preliminary regional PBPK model of lung metabolism for improving species dependent descriptions of 1,3-butadiene and its metabolites","volume":"238","author":"Campbell","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ijpx.2026.100586_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/1061186X.2012.693499","article-title":"Strategies for non-invasive delivery of biologics","volume":"20","author":"Chung","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpx.2026.100586_bb0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/jamp.2011.0916","article-title":"Aerosol deposition in health and disease","volume":"25","author":"Darquenne","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100586_bb0050","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100586_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1164\/rccm.201312-2235OC","article-title":"The effect of inhaled IFN-\u03b2 on worsening of asthma symptoms caused by viral infections. A randomized trial","volume":"190","author":"Djukanovi\u0107","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijpx.2026.100586_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176510","article-title":"Adequacy of laser diffraction for soil particle size analysis","volume":"12","author":"Fisher","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpx.2026.100586_bb0065","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2026.100586_bb0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fphar.2016.00181","article-title":"Measurements of deposition, lung surface area and lung fluid for simulation of inhaled compounds","volume":"7","author":"Fr\u00f6hlich","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","article-title":"A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases","volume":"20","author":"He","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0080","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10928-022-09824-w","article-title":"Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans","volume":"49","author":"Jagdale","year":"2022","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ijpx.2026.100586_bb0085","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11095-010-0098-6","article-title":"Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons","volume":"27","author":"Kagan","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100586_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209587","article-title":"Quantitative systems pharmacology of interferon alpha administration: a multi-scale approach","volume":"14","author":"Kalra","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpx.2026.100586_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1013509","article-title":"A comparative computational analysis of IFN-alpha pharmacokinetics and its induced cellular response in mice and humans","volume":"21","author":"Kalra","year":"2025","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00133-06","article-title":"Interpretation of antibiotic concentration ratios measured in epithelial lining fluid","volume":"52","author":"Kiem","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2026.100586_bb0105","doi-asserted-by":"crossref","DOI":"10.1242\/dev.198192","article-title":"Mammalian tracheal development and reconstruction: insights from in vivo and in vitro studies","volume":"148","author":"Kishimoto","year":"2021","journal-title":"Development"},{"key":"10.1016\/j.ijpx.2026.100586_bb0110","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.drudis.2022.02.003","article-title":"Emerging trends in pulmonary delivery of biopharmaceuticals","volume":"27","author":"Kunde","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpx.2026.100586_bb0115","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1073\/pnas.82.10.3281","article-title":"Murine interferon-beta receptor-mediated endocytosis and nuclear membrane binding","volume":"82","author":"Kushnaryov","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijpx.2026.100586_bb0120","first-page":"12","article-title":"Pulmonary delivery of biological drugs","author":"Liang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100586_bb0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0006-291X(86)90273-1","article-title":"Transport of gamma-interferon into the cell nucleus may be mediated by nuclear membrane receptors","volume":"138","author":"MacDonald","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpx.2026.100586_bb0130","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/ar.21208","article-title":"Stochastic morphometric model of the BALB\/c mouse lung","volume":"293","author":"Madl","year":"2010","journal-title":"Anat. Rec. (Hoboken)"},{"key":"10.1016\/j.ijpx.2026.100586_bb0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ijpx.2026.100586_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004782","article-title":"Leukocyte-derived IFN-\u03b1\/\u03b2 and epithelial IFN-\u03bb constitute a compartmentalized mucosal defense system that restricts enteric virus infections","volume":"11","author":"Mahlak\u00f5iv","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijpx.2026.100586_bb0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1042\/BJ20070605","article-title":"Comparable potency of IFNalpha2 and IFNbeta on immediate JAK\/STAT activation but differential down-regulation of IFNAR2","volume":"407","author":"Marijanovic","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijpx.2026.100586_bb0150","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/089426803772455622","article-title":"Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations","volume":"16","author":"Mitchell","year":"2003","journal-title":"J. Aerosol. Med."},{"key":"10.1016\/j.ijpx.2026.100586_bb0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2125.2000.00106.x","article-title":"Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?","volume":"49","author":"Newman","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0160","first-page":"25","article-title":"The current and promising oral delivery methods for protein- and peptide-based drugs","author":"Nicze","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijpx.2026.100586_bb0165","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/ar.20593","article-title":"Predicted tracheobronchial and pulmonary deposition in a murine asthma model","volume":"290","author":"Oldham","year":"2007","journal-title":"Anat. Rec. (Hoboken)"},{"key":"10.1016\/j.ijpx.2026.100586_bb0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1248\/cpb.c25-00552","article-title":"Inhaled biologics: overcoming challenges and recent advances","volume":"74","author":"Onoue","year":"2026","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ijpx.2026.100586_bb0175","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/molecules14093754","article-title":"Nasal delivery of high molecular weight drugs","volume":"14","author":"Ozsoy","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2026.100586_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpx.2026.100586_bb0185","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s40121-024-01024-y","article-title":"Safety, tolerability, and pharmacokinetics of nebulized GB05-human IFN\u03b11b inhalation solution: a randomized, placebo-controlled, dose-escalation phase I study in healthy chinese adult volunteers","volume":"13","author":"Peng","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ijpx.2026.100586_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10928-014-9402-0","article-title":"Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory","volume":"42","author":"Sepp","year":"2015","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ijpx.2026.100586_bb0195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ijpx.2026.100586_bb0200","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1208\/s12249-023-02689-3","article-title":"Systemically administered anti-uPAR antibody plasma and lung ELF pharmacokinetics characterized by minimal lung PBPK model","volume":"24","author":"Sharma","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2026.100586_bb0205","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/psp4.13245","article-title":"Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab","volume":"14","author":"Sharma","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.addr.2018.06.004","article-title":"Repurposing of gamma interferon via inhalation delivery","volume":"133","author":"Smaldone","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2026.100586_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.608645","article-title":"Importance of Type I and III interferons at respiratory and intestinal barrier surfaces","volume":"11","author":"Stanifer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0220","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/13543776.2020.1741547","article-title":"Patented therapeutic drug delivery strategies for targeting pulmonary diseases","volume":"30","author":"Thakur","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ijpx.2026.100586_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357011775145","article-title":"The biopharmaceutical aspects of nasal mucoadhesive drug delivery","volume":"53","author":"Ugwoke","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/08942680152007954","article-title":"Validation of laser diffraction method as a substitute for cascade impaction in the European Project for a Nebulizer Standard","volume":"14","author":"Vecellio None","year":"2001","journal-title":"J. Aerosol. Med."},{"key":"10.1016\/j.ijpx.2026.100586_bb0235","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/psp4.70043","article-title":"An integrative mechanistic model of Type 1 IFN-mediated inflammation in systemic lupus erythematosus","volume":"14","author":"Volkova","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0240","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.xphs.2017.03.038","article-title":"Physiologically based pharmacokinetic modeling of therapeutic proteins","volume":"106","author":"Wong","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100586_bb0245","article-title":"Interferon Receptor trafficking and Signaling: journey to the Cross roads","volume":"11","author":"Zanin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijpx.2026.100586_bb0250","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1208\/s12248-012-9332-y","article-title":"Applications of human pharmacokinetic prediction in first-in-human dose estimation","volume":"14","author":"Zou","year":"2012","journal-title":"AAPS J."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:15:18Z","timestamp":1793031318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156726001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":50,"alternative-id":["S2590156726001064"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100586","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating in vitro aerosol characterization and cross-species PBPK modeling to predict human lung exposure of inhaled therapeutic proteins","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100586"}}